Ikgdar 100mg Injection contains Rituximab, a chimeric monoclonal antibody targeting the CD20 antigen found on the surface of B-lymphocytes. It is indicated for the treatment of various B-cell malignancies, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, as well as certain autoimmune disorders such as rheumatoid arthritis. Rituximab exerts its therapeutic effect by binding to the CD20 antigen, leading to B-cell depletion through mechanisms including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis. Ikgdar 100mg Injection is administered intravenously under strict medical supervision, with dosage and treatment schedules tailored according to the specific indication and patient response. Prior to infusion, premedication with antihistamines and corticosteroids is recommended to minimize infusion-related reactions. Patients should be monitored closely for adverse effects such as infusion reactions, infections, and hematologic toxicities. Contraindications include known hypersensitivity to Rituximab or murine proteins. Caution is advised in patients with active infections or compromised immune systems. Ikgdar 100mg Injection should be used as part of a comprehensive treatment plan, with regular monitoring of clinical and laboratory parameters to assess efficacy and safety.